Showing results (71-80 of 160) with videos related to

Sort By:
Pageof 16
Progress in Biophysics and Molecular Biology|May 15, 2004
Modelling cell population growth with applications to cancer therapy in human tumour cell linesBritta Basse, Bruce C Baguley, Elaine S Marshall, et al.
Epigenetics|January 15, 2015
Epigenetic regulation in human melanoma: past and futureDebina Sarkar, Euphemia Y Leung, Bruce C Baguley, et al.
Frontiers in Genetics|November 18, 2014
Keeping abreast with long non-coding RNAs in mammary gland development and breast cancerHerah Hansji, Euphemia Y Leung, Bruce C Baguley, et al.
Plos One|July 7, 2015
Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell LinesEuphemia Y Leung, Marjan Askarian-Amiri, Graeme J Finlay, et al.
Bulletin of Mathematical Biology|May 17, 2005
Modelling the flow [corrected] cytometric data obtained from unperturbed human tumour cell lines: parameter fitting and comparisonBritta Basse, Bruce C Baguley, Elaine S Marshall, et al.
Cancer Genetics|October 25, 2011
Centrosomal dysregulation in human metastatic melanoma cell linesGeoffrey A Charters, Clare J Stones, Andrew N Shelling, et al.
Investigational New Drugs|November 23, 2011
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cellsEuphemia Leung, Gordon W Rewcastle, Wayne R Joseph, et al.
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|October 5, 2017
The Genes of Life and Death: A Potential Role for Placental-Specific Genes in Cancer: Active retrotransposons in the placenta encode unique functional genes that may also be used by cancer cells to promote malignancyErin C Macaulay, Aniruddha Chatterjee, Xi Cheng, et al.
Investigational New Drugs|June 23, 2010
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposideCatherine J Drummond, Graeme J Finlay, Laura Broome, et al.
Investigational New Drugs|August 11, 2010
In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinomaYing Yi Chen, Graeme J Finlay, James A Kirker, et al.
Pageof 16